Results after Four Years of Screening for Prostate Cancer with PSA and MRI – Advanced Prostate Cancer Consensus Conference

Advanced Prostate Cancer Consensus Conference posted on LinkedIn about recent paper by Jonas Hugosson et al., titled “Results after Four Years of Screening for Prostate Cancer with PSA and MRI” published on The New England Journal of Medicine.

Authors: Jonas Hugosson, Rebecka Arnsrud Godtman, Jonas Wallstrom, Ulrika Axcrona, Anders Bergh, Lars Egevad, Kjell Geterud, Mikael Hellstrom

“Results after Four Years of Screening for Prostate Cancer with PSA and MRI out on New England Journal of Medicine GÖTEBORG-2 ISRCTN

This study assessed the efficacy and safety of MRI-based prostate cancer screening in men aged 50 to 60, comparing MRI-targeted biopsy with systematic biopsy.

Men with elevated PSA levels underwent MRI and were randomly assigned to either systematic biopsy or MRI-targeted biopsy groups. After a median follow-up of 3.9 years, MRI-targeted biopsy detected fewer clinically insignificant cancers compared to systematic biopsy (2.8% vs. 4.5%), with a 57% lower risk of overdiagnosis. The detection rates for clinically significant cancers and high-risk cancers were similar between the groups, with few adverse events reported.

The findings suggest that MRI-targeted biopsy reduces unnecessary prostate cancer diagnoses without significantly increasing the risk of missing advanced cancers.”

Source: Advanced Prostate Cancer Consensus Conference/LinkedIn